Sebastiano Buti

Also affiliated with University of Macerata

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

6in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 6 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 7 papers. Top paper: “Cabozantinib as First-line Treatment in Patients With Metastatic Collecting Duct Renal Cell Carcinoma”.

Cabozantinib as First-line Treatment in Patients With Metastatic Collecting Duct Renal Cell Carcinoma

JAMA Oncology(2022)10.1001/jamaoncol.2022.0238

N/A

1.9DataRank · unranked

61 citations

Pierangela Sepe, Melanie Claps, Sebastiano Buti, Maurizio Colecchia, Patrizia Giannatempo +7 more

The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study

Journal of Translational Medicine(2022)10.1186/s12967-022-03601-6

N/A

0.477DataRank · unranked

23 citations

Alessio Signori, Giuseppe Luigi Banna, Annalice Gandini, Giuseppe Fornarini, Alessandra Damassi +35 more

Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis

Therapeutic Advances in Urology(2021)10.1177/17562872211053189

N/A

0.449DataRank · unranked

19 citations

Carlo Messina, Chiara Airoldi, Sebastiano Buti, Giandomenico Roviello, Alessia Mennitto +4 more

Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives

Drug Design, Development and Therapy(2018)10.2147/dddt.s124380

N/A

0.434DataRank · unranked

17 citations

Paola Bordi, Alessandro Leonetti, Sebastiano Buti, Marcello Tiseo, Francesco Facchinetti

Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study

Cancer Immunology, Immunotherapy(2023)10.1007/s00262-023-03469-5

N/A

0.385DataRank · unranked

12 citations

Zin W. Myint, Thomas Büttner, Hideki Takeshita, Yohei Okada, Elaine T. Lam +38 more

When is immunotherapy too much? The case of favorable-risk metastatic renal cell carcinoma

Critical Reviews in Oncology/Hematology(2026)10.1016/j.critrevonc.2026.105238

N/A

0.104DataRank · unranked

1 citations

Betty Dalla Valle, Alessandro Acunzo, Pietro Tuttobene, Prisca Tamarozzi, Virginia Agnetti +5 more

Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors

JNCI Journal of the National Cancer Institute(2023)10.1093/jnci/djad155

N/A

0DataRank · unranked

56 citations

Amin H. Nassar, Gregory R. Pond, Tony Zhuang, Viraj A. Master, Bassel Nazha +50 more